Patient safety outcomes for continuous infusion vancomycin as outpatient parenteral antimicrobial therapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2833 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Russell J Benefield und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Anti-Infective Agents, Renal Insufficiency, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Administration of vancomycin as a continuous infusion has been associated with reduced nephrotoxicity. Given limited published experience with continuous infusion vancomycin in outpatient parenteral antimicrobial therapy (OPAT) programs, we reviewed outcomes from our center.
Methods
This was a retrospective, single‐center study of adult patients receiving vancomycin OPAT as continuous or intermittent infusion for an intended treatment duration of at least 7 days. The primary outcome was time to nephrotoxicity with continuous versus intermittent infusion vancomycin while on OPAT; additional outcomes included time to any vancomycin‐associated adverse event, time to 60‐day death or readmission, and time to 60‐day emergency department encounter. Proportional hazards modeling was used to identify variables independently associated with outcomes, as well as assess the strength of association of continuous infusion with each outcome.
Results
Four‐hundred ninety‐two patients were included: 118 treated with continuous and 374 with intermittent vancomycin infusion. Continuous infusion was not associated with lower rates of nephrotoxicity compared to intermittent infusion (adjusted hazard ratio (aHR) 0.72, 95% CI: 0.35–1.50). There were no advantages of continuous over intermittent infusion in the rates of any adverse event (aHR 0.93, 95% CI: 0.56–1.53), 60‐day death or readmission (aHR 1.04, 95% CI: 0.68–1.61), or 60‐day emergency department encounter (aHR 1.17, 95% CI: 0.68–1.99). Vancomycin area under the concentration‐time curve (AUC) at discharge was the only modifiable factor identified that was independently associated with patient safety outcomes.
Conclusion
There was no appreciable benefit of continuous infusion vancomycin on outpatient safety outcomes. AUC‐centered dosing approaches warrant further investigation as strategies to improve vancomycin safety in OPAT programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.
- Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.
- Data Sciences Services, University of Utah Health, Salt Lake City, Utah, USA.
- Division of Infectious Diseases, University of Utah Health, Salt Lake City, Utah, USA.
ORCID-Profile: Russell J Benefield, Brandon Tritle, Laura K Certain
Zitieren
APA
Benefield, R. J., McDonald, J., Newman, M., Tritle, B., & Certain, L. K. (2023). Patient safety outcomes for continuous infusion vancomycin as outpatient parenteral antimicrobial therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2833
Vancouver
Benefield RJ, McDonald J, Newman M, Tritle B, Certain LK. Patient safety outcomes for continuous infusion vancomycin as outpatient parenteral antimicrobial therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2833
BibTeX
@article{Benefield2023,
author = {Benefield, Russell J and McDonald, Joshua and Newman, Michael and Tritle, Brandon and Certain, Laura K},
title = {Patient safety outcomes for continuous infusion vancomycin as outpatient parenteral antimicrobial therapy},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2833}
}
EUVIMED